UroMems, a company based in Grenoble, France, and Minneapolis, MN, developing implantable mechatronics technology, has raised $47 million in Series C funding.
Investors
The round was led by:
- Crédit Mutuel Innovation
- European Innovation Council
Existing investors also participated:
- Wellington Partners
- Bpifrance
- Supernova Invest
- Hil-Invent
- b-to-v Partners
- Financière Arbevel
Funding Purpose
The funds will be utilized to support large-scale U.S. and European pivotal clinical trials of the UroActive™ implant.
About UroMems
- CEO: Hamid Lamraoui
- CMO: Professor Pierre Mozer
UroActive™ is an active implantable electronic artificial urinary sphincter designed to compensate for sphincter insufficiency in patients with Stress Urinary Incontinence (SUI). This condition affects both men and women. The device is built on a bionic platform that uses embedded smart, digital, and robotic systems to create a personalized treatment algorithm based on patient data.
Key Features:
- Optimized safety and performance
- Enhanced patient experience
- Improved surgeon convenience
UroActive™ is protected by more than 150 patents and aims to overcome the limitations of current solutions. The device has not yet received marketing authorization from the FDA and is not available for sale in the United States or the EU.
